AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15175957
Drug: Post-chemotherapy blastemal
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-chemotherapy blastemal predominant subtype
Trial: 11597384
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care protocol intervention (tooth brushing, 0.2% chlorhexidine mouth rinse, 0.9% saline rinse)
Trial: 11597384
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral care protocol)
Trial: 9589757
Drug: Assertive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive community treatment (ACT)
Trial: 29127458
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 (IV; 0.2-120 mg)
Trial: 29127458
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 (SC; 40-120 mg)
Trial: 29127458
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 (IV; doses ≥ 20 mg)
Trial: 29127458
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 (SC; 120 mg)
Trial: 26531051
Drug: Topical natamycin
RxNorm normalized name: Natamycin
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical natamycin
Trial: 20420756
Drug: Convenience drink
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Convenience drink supplemented with n‐3 fatty acids (200 mg EPA and 300 mg DHA)
Trial: 20420756
Drug: Placebo (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.1 g linoleic acid from maize oil)
Trial: 15970792
Drug: FSH dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH dose of 150 U/day (Group I, Ser/Ser)
Trial: 15970792
Drug: FSH dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH dose of 225 U/day (Group II, Ser/Ser)
Trial: 15970792
Drug: FSH dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH dose of 150 U/day (Group III, Asn/Asn)
Trial: 10589812
Drug: Instructional leaflet
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Instructional leaflet (group L)
Trial: 9107182
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg BID)
Trial: 23047595
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose telmisartan (80 mg/day) combined with trichlormethiazide (1 mg/day)
Trial: 23047595
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of telmisartan (40 mg/day), trichlormethiazide (1 mg/day), and amlodipine (5 mg/day)
Trial: 12628899
Drug: Distraction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distraction therapy with nature sights and sounds (nature scene murals and nature sounds tape)
Trial: 10669333
Drug: Potent antiretroviral
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent antiretroviral therapy (protease inhibitor‐containing)
Trial: 2023702
Drug: High-dose prochlorperazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prochlorperazine infusion and dexamethasone (HDPD)
Trial: 2023702
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide and dexamethasone (HDMD)
Trial: 7067184
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release metoprolol (200 mg durule)
Trial: 7067184
Drug: Conventional metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional metoprolol (100 mg twice daily)
Trial: 28498078
Drug: Patient self-administration
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient self-administration of Kinetic Oscillatory Stimulation (KOS) catheter
Trial: 28498078
Drug: Patient self-administration
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient self-administration of KOS catheter
Trial: 25296740
Drug: Cryo-chamber therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryo-chamber therapy at -67 °C
Trial: 25296740
Drug: Sham cryo-chamber
RxNorm normalized name: HOLDING CHAMBER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham cryo-chamber therapy at -5 °C
Trial: 23819221
Drug: Electroacupuncture (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (1 Hz/50 Hz) for 30 min once daily for 14 days
Trial: 23819221
Drug: Naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4 mg/kg for first 3 days, 0.2 mg/kg for 7 days, 0.1 mg/kg afterwards)
Trial: 23819221
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication (mild hypothermia, dehydration medicines, hormonal therapy, vascular dilation, cerebral nutrition, anti-inflammation)
Trial: 19167143
Drug: Inadequate social
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inadequate social support, unstable job, and the use of alcohol and drugs
Trial: 27835716
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) treatment
Trial: 9121502
Drug: Anti-GM1 antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-GM1 antibodies
Trial: 9121502
Drug: Anti-GQ1b antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-GQ1b antibodies
Trial: 9121502
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with anti-GM1 antibodies
Trial: 9121502
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with anti-GQ1b antibodies
Trial: 8002061
Drug: Morning dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dose of hydrocortisone (20 mg/m2 daily)
Trial: 8002061
Drug: Night dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night dose of hydrocortisone (20 mg/m2 daily)
Trial: 3042841
Drug: Naloxone HCl
RxNorm normalized name: naloxone HCl
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone HCl 2.0 mg/kg IV bolus
Trial: 3042841
Drug: Naloxone HCl
RxNorm normalized name: naloxone HCl
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone HCl 0.1 mg/kg IV bolus
Trial: 25402372
Drug: metformin 1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 1700 mg/d plus vildagliptin 100 mg/d
Trial: 25402372
Drug: metformin 1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 1700 mg/d
Trial: 9364693
Drug: Maternal HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal HBV DNA < 150 pg ml-1
Trial: 9364693
Drug: Maternal HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal HBV DNA > 150 pg ml-1
Trial: 1551035
Drug: terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 120 mg twice daily
Trial: 29580640
Drug: EasySix™ vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EasySix™ vaccine
Trial: 27559737
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline injection (pain)
Trial: 22828857
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil (0.05-0.125 μg/kg/min) and propofol (1-3 mg/kg/h)
Trial: 22828857
Drug: Propofol (1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1-3 mg/kg/h)
Trial: 20653166
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (dissolving phlegm-stasis)
Trial: 16275486
Drug: Betaxolol hydrochloride
RxNorm normalized name: Betaxolol Hydrochloride
DrugBank: Betaxolol (DB00195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaxolol hydrochloride (5 mg daily for 3 weeks)
Trial: 12175392
Drug: tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine 2 mg twice daily for 10 weeks
Trial: 12175392
Drug: oxybutynin 5
RxNorm normalized name: oxyBUTYnin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxybutynin 5 mg twice daily for 10 weeks
Trial: 10442207
Drug: sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained release capsules containing 100 mg tramadol hydrochloride, total of 6 capsules at intervals of 12 h
Trial: 10442207
Drug: instant release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: instant release capsules containing 50 mg tramadol hydrochloride, total of 12 capsules at intervals of 6 h
Trial: 7598920
Drug: eltanolone 0.58
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eltanolone 0.58 mg/kg
Trial: 7598920
Drug: propofol 1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol 1.7 mg/kg
Trial: 29373884
Drug: Progesterone suppositories
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone suppositories (400 mg per night) until delivery or completion of the 34th gestational week
Trial: 26480548
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy at Shenmen (HT 7), Baihui (GV 20), Yintang (GV 29), Hegu (LI 4), Taichong (LR 3), needles retained for 20 min, treatment once a day for 2 weeks (1 session).
Trial: 26480548
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of trazodone, 100 mg, once a day for 2 weeks (1 session).
Trial: 23567596
Drug: P. ginseng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. ginseng (100 mg/d)
Trial: 23567596
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg/d)
Trial: 21766893
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a greater chance of success
Trial: 21766893
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with lower cost
Trial: 21766893
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with shorter duration before being able to exercise free of pain
Trial: 21766893
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with lower chance of side effects
Trial: 21766893
Drug: Injections as
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections as a stand-alone treatment
Trial: 21766893
Drug: 10% increase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% increase in chance of treatment success
Trial: 11574347
Drug: Midazolam (0.025,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.025, 0.05, and 0.1 mg/kg)
Trial: 11574347
Drug: Propofol (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.25, 0.5, and 1.0 mg/kg)
Trial: 9693434
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (non-NPPV)
Trial: 29688873
Drug: Dialectical Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavioural Therapy (DBT) for 12 weeks
Trial: 21736507
Drug: Sequential bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential bilateral rTMS
Trial: 18575851
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg orally
Trial: 12218529
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion (0.2 mg/kg bolus followed by 3, 5, or 7 microg/kg/min infusion)
Trial: 8599955
Drug: 99mTc-labelled antibodies
RxNorm normalized name: technetium (99mTc) antiCarcinoEmbryonicAntigen antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-labelled antibodies against granulocyte non-specific cross-reacting antigen-95
Trial: 1924659
Drug: mianserin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin (30 mg to 150 mg)
Trial: 1924659
Drug: amitriptyline (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amitriptyline (60 mg to 300 mg)
Trial: 1924659
Drug: placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (1 to 5 capsules at bedtime)
Trial: 7051248
Drug: Parenteral trimethoprim‐sulfamethoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral trimethoprim‐sulfamethoxazole and carbenicillin (TMP‐SMZ‐C)
Trial: 7051248
Drug: Gentamicin and
RxNorm normalized name: Gentamicin and prednisolone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin and carbenicillin (G‐C)
Trial: 29398152
Drug: Daily online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily online CBCT IGRT (7 mm margins to PTV)
Trial: 29398152
Drug: Weekly offline
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly offline portal imaging (15 mm margins to PTV)
Trial: 22485048
Drug: Coad (ACWY-TT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coad (ACWY-TT with seasonal influenza vaccine)
Trial: 20331579
Drug: 5 apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 apheresis treatments
Trial: 20331579
Drug: 10 apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 apheresis treatments
Trial: 12900242
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment for 3+ cataracts
Trial: 12900242
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment for 4+ cataracts
Trial: 12900242
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment for all cataract densities
Trial: 10919019
Drug: Self-expanding metal
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-expanding metal stent with initial laser therapy (group 2a)
Trial: 30621948
Drug: Device therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device therapy in women
Trial: 29526837
Drug: Core and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core and mobility training (EG; n=8) - 2 weekly sessions of 50 minutes for 10 weeks
Trial: 26681684
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy with letrozole (arm A)
Trial: 26681684
Drug: Sequential radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radiotherapy with letrozole (arm B)
Trial: 25194287
Drug: Strategy of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy of adjusting therapy to achieve and maintain a target NT-proBNP level of <1,000 pg/ml
Trial: 25194287
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (optimized guideline-recommended therapy)
Trial: 22762346
Drug: DHEP-heparin plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEP-heparin plaster
Trial: 10362152
Drug: Methotrexate, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate, 50 mg/m2
Trial: 10362152
Drug: 6‐mercaptopurine, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐mercaptopurine, 200 mg
Trial: 30882641
Drug: Multimodal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal intervention involving nurses (reinforcing knowledge on antibiotics and UTI, decision aid diagram, communication skills improvement, increased involvement in prescription process).
Trial: 26921746
Drug: Losartan (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (12.5 mg twice per day for the 1st week, 25 mg twice per day during the 2nd week, and 75 mg/d from the 3rd week to the end of the 16th week)
Trial: 23074234
Drug: Intensive i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive i.v. insulin therapy (BG = 70-110 mg/dl)
Trial: 23074234
Drug: Standard s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard s.c. insulin therapy (BG = 70-180 mg/dl)
Trial: 23074234
Drug: Intensive i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive i.v. insulin therapy
Trial: 23074234
Drug: Standard s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard s.c. insulin therapy
Trial: 15898439
Drug: Exchange of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exchange of cerebrospinal fluid and small dose of urokinase injection
Trial: 12472706
Drug: Diclofenac suppositories
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac suppositories (approximately 1 mg x kg(‐1))
Trial: 9824788
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral ganciclovir (6,000 mg/day)
Trial: 9824788
Drug: Ganciclovir 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 2,000 mg every 8 hours alone
Trial: 9824788
Drug: Ganciclovir 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 2,000 mg every 8 hours in combination with didanosine 200 mg every 12 hours
Trial: 2732807
Drug: RRR‐alpha‐tocopherol 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR‐alpha‐tocopherol 600 mg (900 IU) daily for 12 weeks
Trial: 25652127
Drug: Monthly sulphadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sulphadoxine-pyrimethamine (SP)
Trial: 25652127
Drug: Daily trimethoprim-sulphamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily trimethoprim-sulphamethoxazole (TS)
Trial: 23623865
Drug: Vaccine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (two enteric-coated tablets consisting of no less than 4.5 log10 TCID50 of live ADV-4 or ADV-7)
Trial: 19794312
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 1700-kcal diet (21% proteins, 27% lipids, 52% carbohydrates), cognitive-behavioural therapy (CBT), sertraline (50-150 mg/day), topiramate (25-150 mg/day)
Trial: 19794312
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: 1700-kcal diet (21% proteins, 27% lipids, 52% carbohydrates), cognitive-behavioural therapy (CBT), sertraline (50-150 mg/day)
Trial: 16954722
Drug: Atazanavir/ritonavir (300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir (300/100 mg once daily)
Trial: 16954722
Drug: Lopinavir/ritonavir (400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (400/100 mg twice daily)
Trial: 2079570
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon alfa‐2a at a dose of 4.5 million units thrice weekly for 4 months
Trial: 492626
Drug: Propoxyphene (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene (64 mg)
Trial: 31815370
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy only (control)
Trial: 20148372
Drug: Caffeine 6
RxNorm normalized name: caffeine 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 6 mg/kg
Trial: 20148372
Drug: Caffeine 9
RxNorm normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 9 mg/kg
Trial: 31488190
Drug: Caffeine 9
RxNorm normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 9 mg/kg (consumers)
Trial: 31488190
Drug: Caffeine 6
RxNorm normalized name: caffeine 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 6 mg/kg (non-consumers)
Trial: 28291185
Drug: Surgical-site injection
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical-site injection containing ropivacaine, epinephrine, and morphine
Trial: 28291185
Drug: Surgical-site injection
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical-site injection
Trial: 24740134
Drug: AB103 high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB103 high-dose (0.5 mg/kg)